 Warfarin
"Warfarin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
| Descriptor ID |
D014859
|
| MeSH Number(s) |
D03.383.663.283.446.520.914 D03.633.100.150.446.520.914
|
| Concept/Terms |
Warfarin- Warfarin
- 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
|
Below are MeSH descriptors whose meaning is more general than "Warfarin".
Below are MeSH descriptors whose meaning is more specific than "Warfarin".
This graph shows the total number of publications written about "Warfarin" by people in this website by year, and whether "Warfarin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 1 | 3 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 1 | 2 | 3 | | 2002 | 2 | 0 | 2 | | 2003 | 2 | 1 | 3 | | 2004 | 1 | 0 | 1 | | 2005 | 6 | 0 | 6 | | 2006 | 3 | 0 | 3 | | 2007 | 2 | 1 | 3 | | 2008 | 5 | 3 | 8 | | 2009 | 3 | 1 | 4 | | 2010 | 1 | 1 | 2 | | 2011 | 3 | 0 | 3 | | 2012 | 3 | 0 | 3 | | 2013 | 4 | 2 | 6 | | 2014 | 8 | 4 | 12 | | 2015 | 4 | 2 | 6 | | 2016 | 6 | 3 | 9 | | 2017 | 8 | 1 | 9 | | 2018 | 4 | 2 | 6 | | 2019 | 1 | 2 | 3 | | 2020 | 3 | 3 | 6 | | 2021 | 1 | 4 | 5 | | 2022 | 2 | 5 | 7 | | 2023 | 1 | 1 | 2 | | 2024 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Warfarin" by people in Profiles.
-
Hanke P, Domingo ME, Salanio G, Ahmed K, Hu J, Hendricks K, Howard J, Hashimura T, Guiliano C, Haan BJ, Ng TH, Kelley D, Knight T, Koopman K, Obstoj M, Breeden T, Sirbu D, Romano M, Harpenau A, Konneker R, Acevedo J, Pan N, Edwin SB. Apixaban versus warfarin for treatment of venous thromboembolism in patients with severe renal impairment: a multicenter study. J Thromb Thrombolysis. 2025 Mar; 58(3):380-390.
-
Fahmi AM, El Bardissy A, Saad MO, Elshafei MN, Bader L, Mahfouz A, Kasem M, Abdelsamad O, Elzouki A, Aquilante CL, Mraiche F, Soaly E, El Madhoun I, Asaad N, Arabi A, Alhmoud E, Elewa H. Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial). Clin Transl Sci. 2024 Jun; 17(6):e13797.
-
Harrington J, Hellkamp AS, Mahaffey KW, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Fox KAA, Singer DE, Goodman SG, Patel MR, Piccini JP. Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis. J Am Heart Assoc. 2024 Jun 04; 13(11):e028951.
-
Anandalwar SP, O'Meara L, Vesselinov R, Zhang A, Baum JN, Cooper A, Decker C, Schroeppel T, Cai J, Cullinane D, Catalano RD, Bugaev N, LeClair M, Feather C, McBride K, Sams V, Leung PS, Olafson S, Callahan DS, Posluszny J, Moradian S, Estroff J, Hochman B, Coleman N, Goldenberg-Sandau A, Nahmias J, Rosenbaum K, Pasley J, Boll L, Hustad L, Reynolds J, Truitt M, Ghneim M. Warfarin, not direct oral anticoagulants or antiplatelet therapy, is associated with increased bleeding risk in emergency general surgery patients: Implications in this new era of novel anticoagulants: An EAST multicenter study. J Trauma Acute Care Surg. 2024 Aug 01; 97(2):225-232.
-
Derington CG, Goodrich GK, Xu S, Clark NP, Reynolds K, An J, Witt DM, Smith DH, O'Keeffe-Rosetti M, Lang DT, Ho PM, Cheetham TC, Comer AC, King JB. Association of Direct Oral Anticoagulation Management Strategies With Clinical Outcomes for Adults With Atrial Fibrillation. JAMA Netw Open. 2023 07 03; 6(7):e2321971.
-
O'Meara L, Zhang A, Baum JN, Cooper A, Decker C, Schroeppel T, Cai J, Cullinane DC, Catalano RD, Bugaev N, LeClair MJ, Feather C, McBride K, Sams V, Leung PS, Olafson S, Callahan DS, Posluszny J, Moradian S, Estroff J, Hochman B, Coleman NL, Goldenberg-Sandau A, Nahmias J, Rosenbaum K, Pasley JD, Boll L, Hustad L, Reynolds J, Truitt M, Vesselinov R, Ghneim M. Anticoagulation in emergency general surgery: Who bleeds more? The EAST multicenter trials ACES study. J Trauma Acute Care Surg. 2023 10 01; 95(4):510-515.
-
Steiner HE, Carrion KC, Giles JB, Lima AR, Yee K, Sun X, Cavallari LH, Perera MA, Duconge J, Karnes JH. Local Ancestry-Informed Candidate Pathway Analysis of Warfarin Stable Dose in Latino Populations. Clin Pharmacol Ther. 2023 03; 113(3):680-691.
-
Bonaca MP, Antman EM, Cunningham JW, Wiviott SD, Murphy SA, Halperin JL, Weitz JI, Grosso MA, Lanz HJ, Braunwald E, Giugliano RP, Ruff CT. Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29; 8(7):695-706.
-
Chew DS, Zhou K, Pokorney SD, Matchar DB, Vemulapalli S, Allen LA, Jackson KP, Samad Z, Patel MR, Freeman JV, Piccini JP. Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis. Ann Intern Med. 2022 09; 175(9):1230-1239.
-
Novak AR, Shakowski C, Trujillo TC, Wright GC, Mueller SW, Kiser TH. Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism. J Thromb Thrombolysis. 2022 Aug; 54(2):276-286.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|